StockNews.AI
FBLG
StockNews.AI
39 days

FibroBiologics to Present at the Advanced Wound Care Summit USA

1. FibroBiologics' CEO will present at a key industry summit on July 15. 2. The presentation will highlight advances in wound healing and psoriasis treatments. 3. CYWC628 therapy offers a new approach to diabetic foot ulcers. 4. Phase 1/2 clinical trials for CYWC628 are set to begin this year. 5. FibroBiologics holds over 275 patents related to chronic disease therapies.

7m saved
Insight
Article

FAQ

Why Bullish?

The upcoming presentation at a summit suggests strong potential for investor interest. Historical examples show that successful presentations often lead to stock price gains in biotech firms.

How important is it?

The announcement of clinical trials and presentations is crucial in biotech, impacting investor sentiment significantly. The continued emphasis on advancing treatments for chronic diseases aligns with growth expectations.

Why Short Term?

The immediate scheduling of a presentation and clinical trial suggests likely short-term price movement. Similar past events often see stock spikes pre- or post-presentation.

Related Companies

AMGNREGNGILD
July 11, 2025 08:30 ET  | Source: FibroBiologics, Inc. HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the Advanced Wound Care Summit USA in Boston, Massachusetts, on July 15, 2025. The presentation will include recent research advances using fibroblast-based technology for indications such as wound healing and psoriasis. “The Advanced Wound Care Summit is an ideal forum to showcase how FibroBiologics is pioneering the next generation of wound healing through our fibroblast-based technology," said Mr. O’Heeron. "Our CYWC628 therapy represents a fundamentally different approach to treating diabetic foot ulcers, one that taps into the body's natural regenerative processes rather than simply managing symptoms. With our Phase 1/2 clinical trial set to kick off later this year, we are poised to deliver potentially transformative outcomes for patients with limited treatment options and high recurrence rates.” Details of the presentation are as follows: Date: Tuesday, July 15, 2025Time: 2 p.m. ETLocation: Marriott Courtyard Boston Downtown The Advanced Wound Care Summit, taking place July 15–17, will bring together global leaders in wound care innovation, clinical research, and advanced therapeutics to address unmet needs in chronic wound management. With a focus on accelerating product development and enhancing patient outcomes, the summit will feature keynote presentations, interactive panels, and strategic networking opportunities. For more information, please visit FibroBiologics’ website or email FibroBiologics at info@fibrobiologics.com. Cautionary Statement Regarding Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the anticipated timing of the initiation of and results from, FibroBiologics’ current and future preclinical studies, clinical trials and research and development programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.  General Inquiries:info@fibrobiologics.com Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@russopr.com Media Contact:Liz PhillipsRusso Partners(347) 956-7697Elizabeth.phillips@russopartnersllc.com

Related News